Noelia has 21 years of drug development experience across biotech and big pharma. She has global experience spanning all phases of clinical development primarily in oncology, cardiology, and rare disease.
Prior to COUR, Noelia served as Vice President of Clinical Operations at Tourmaline Bio, where she played a key role in supporting the company’s successful $1.4 billion acquisition by Novartis.
She is an impact driven leader with deep expertise in global clinical operations strategy and execution, supported by strong progression of roles in Clinical Operations and Program Management at AVEO Oncology (LG Chem), Amgen, Pfizer, Odonate Therapeutics and Tourmaline Bio. She is experienced in inspection readiness and onsite global regulatory engagement, CTD development supporting marketing authorization applications, and Advisory Board/Safety Committee governance. Her experience includes small molecules and biologics, notably: Xeljanz® (tofacitinib), Besponsa® (inotuzumab ozogamicin), Daurismo® (glasdegib), Corlanor® (ivabradine), and pacibekitug (anti-IL-6).